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293 Limited clinical data are available on hereditary
angioedema treatments during pregnancy. A case series of
14 pregnant women demonstrated that treatment with
recombinant human C1 inhibitor was generally safe and
well tolerated.TO THE EDITOR:
Hereditary angioedema (HAE) is a rare (<1 in 50,000) ge-
netic disorder characterized by episodes of cutaneous and
mucosal angioedema.1 HAE is caused by insufficient suppression
of complement and contact-system cascades due to a deficiency
of functional C1 inhibitor (C1-INH).1 It has been demonstrated
that HAE abdominal attacks are more frequent during preg-
nancy, but there is no consensus on which trimester is most
associated with increased attack rates.2,3 Some data suggest that
more severe attacks and symptoms occur during the first
trimester,2 whereas other data suggest a greater number of attacks
in the second and third trimesters.3 Changes in hormone levels
during pregnancy may exacerbate HAE attacks, and concernsLE I. Patients’ demographic characteristics and HAE attack mana





ent 1 27 65.5 2100 IU
ent 2 NR 72.0 2100-4200 IU
ent 3 21 84.0 2100 IU
ent 4 29 120.0 4200 IU
ent 5 24 NR 2100-4200 IU
ent 6 30 63.6 50 IU/kg
ent 7 26 NR 4200 IU
ent 8 33 NR 50 IU/kg
ent 9 23 NR 4200 IU
ent 10 20 80-82 4200 IU
ent 11 25 63 2100-3150 IU†
ent 12 37 66 4200 IU
ent 13 17 55 2700-4200 IU
ent 14 37 75 4200 IU
Not reported.
eived rhC1-INH during pregnancy a “few” times and a prophylactic dose of rhC1-I
erall, 25,900 IU of rhC1-INH administered during pregnancy.
eived an initial dose of 3150 IU for an attack; a second dose (2100 IU) was admini
otal of 24 acute treatments and 26 prophylactic treatments (rhC1-INH 3 times weekl
ven treatments for HAE attacks and 1 prophylactic treatment.
8
with administration of certain medications during pregnancy can
complicate HAE management.1-3
Recombinant human C1-INH (rhC1-INH) is indicated in
the United States for the treatment of acute attacks in adolescents
and adults with HAE. Data have demonstrated that rhC1-INH
is efficacious and well tolerated for the acute treatment of HAE
attacks,4,5 and as prophylaxis in patients with frequent attacks of
HAE.6 However, data are limited on the treatment of HAE
attacks in women who are pregnant. The objective of this current
communication was to further characterize the clinical outcomes
of pregnant patients with HAE who were treated with rhC1-
INH to manage HAE attacks, with the intent that these real-
world findings will build a knowledge base around the use of
rhC1-INH in this patient population.
Identified as part of routine pharmacovigilance or clinical trial
participation, pregnant women with HAE from the United
States and Europe who received rhC1-INH were followed to
term. Adverse events that occurred during pregnancy were
assessed and neonatal outcomes were reported.
Fourteen pregnant women aged 17 to 37 years withHAE treated
with rhC1-INH were identified (Table I) through spontaneous
event reporting to Pharming Group NV (n ¼ 13) or during
participation in a Pharming-sponsored clinical trial (n¼ 1). Two of
these 14 patients had anHAE type identified; both had type IHAE.
Patient 9 received an unspecified number of treatments for HAE
attacks, as well as a 4200-IU dose predelivery as short-term pro-
phylaxis. Patient 12 received rhC1-INH for 24 attacks and received
26 rhC1-INH doses as prophylaxis. Patient 13 received rhC1-INH
for 11 attacks and received 1 rhC1-INH dose as prophylaxis. The
other 11 patients were treated with rhC1-INH (range, 2100-4200
IU) for 1 (n¼ 1 patient), 2 (n¼ 2), 4 (n¼ 1), 6 (n¼ 1), 8 (n¼ 2), 9
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stered 18 h later when symptoms did not resolve.
y).
TABLE II. Additional information on childbirth outcomes
Patient Delivery method Outcome
Patient 1 Vaginal  Gestational age at time of first exposure: w2 mo
 Live birth at 38 wk (2850 g)
 Apgar score* ¼ 10 (at 1 and 5 min)
 No fetal distress, birth defects, or congenital abnormalities
Patient 2 Vaginal  Gestational age at time of first exposure: w1 wk
 Live birth at 42 wk (3690 g)
 No fetal distress, birth defects, or congenital abnormalities
Patient 3 Cesarean  Gestational age at time of first exposure: w19 wk
 Live birth at 39 wk (3370 g)
 No fetal distress, birth defects, or congenital abnormalities
Patient 4 Vaginal  Live birth at 42 wk (3370 g)
 Apgar score* ¼ 10 (at 1 and 5 min)
 No fetal distress, birth defects, or congenital abnormalities
Patient 5 NR  Live birth
 No fetal distress, birth defects, or congenital abnormalities
Patient 6 NR  Gestational age at time of first exposure: 8 wk
 Live birth
 No fetal distress, birth defects, or congenital abnormalities
Patient 7 NR  Live birth
 No fetal distress, birth defects, or congenital abnormalities
Patient 8 NR  Gestational age at time for first exposure: w16 wk
 Live birth at 41 wk
 No fetal distress, birth defects, or congenital abnormalities
Patient 9 Cesarean  Live birth at 41 wk (3480 g)
 Apgar score* ¼ 8-9
 No fetal distress, birth defects, or congenital abnormalities
Patient 10 Vaginal  Gestational age at time of first exposure: 29 wk
 Live birth at 41 wk (2700 g)
 Apgar score* ¼ 10
 No fetal distress, birth defects, or congenital abnormalities
Patient 11 Vaginal  Gestational age at the time of first exposure: 14 wk
 Live birth at 39 wk (2470 g)
 Apgar score* ¼ 10
 No fetal distress, birth defects, or congenital abnormalities
Patient 12 Vaginal  Gestational age at the time of first exposure: 8-12 wk
 Live birth at 38 wk
 No fetal distress, birth defects, or congenital abnormalities
Patient 13 Vaginal  Gestational age at the time of first exposure: 24-25 wk
 Live birth at 39 wk
 No fetal distress, birth defects, or congenital abnormalities
Patient 14 Vaginal  Gestational age at the time of first exposure: 4 wk
 Live birth at 41 wk
 Apgar score* ¼ 8-9
 No fetal distress, birth defects, or congenital abnormalities
NR, Not reported.
*Possible score 0 to 10, with range of 7-10 classified as reassuring.
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requiredmore than 1 dose ofmedication. The attack experienced by
this patient occurred at multiple locations (abdomen, urogenital
region, and left hand) and was treated with an initial rhC1-INH
dose of 3150 IU. When symptoms had not resolved 18 hours
later, a second rhC1-INH dose of 2100 IU was administered and
resulted in a rapid remission of symptoms.
Regarding anatomical locations of special interest, 10 life-
threatening upper airway HAE attacks occurred in 2 patients(patients 3 [facial/laryngeal] and 7 [laryngeal]). Improvement in
clinical symptoms was reported for all 10 of these HAE attacks
within 2 to 4 hours after rhC1-INH administration. In addition,
patient 4 experienced 4 separate facial HAE attacks, each suc-
cessfully treated with a single rhC1-INH dose, with no addi-
tional medication required.
There were no adverse events considered related to rhC1-INH
treatment during the pregnancy period; patient 6 experienced an
episode of nausea, vomiting, and diarrhea, but it was considered
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2940 CLINICAL COMMUNICATIONSby the health care provider to be related to a “stomach bug.” Of
the 14 pregnant women in this case series, birth delivery method
details were available for 10. Eight had vaginal deliveries and 2
had cesarean deliveries, all without complications (Table II). All
14 women gave birth at full term to healthy babies.
There are no published clinical studies that compare HAE
treatment regimens during pregnancy. However, expert
consensus recommends C1 inhibitors as first-line treatment for
acute HAE attacks during pregnancy on the basis of its safety
profile.1,7,8 When a C1 INH is unavailable, long-term prophy-
lactic treatment with tranexamic acid could be an option.1,7
Because data regarding the safety of HAE treatment during
pregnancy are limited, icatibant and ecallantide are not recom-
mended for women who are pregnant.1,7 Attenuated androgens
are contraindicated during pregnancy because they have been
shown to cross the placenta and may impact fetal develop-
ment.1,7 Before the current case series, there was a report of 3
pregnant patients who were treated with a median dose of 4200
IU rhC1-INH for 50 HAE attacks, with time to complete
symptom resolution of 17 hours (range, 3-48 hours).9 One pa-
tient had 4 HAE attacks (gastrointestinal and laryngeal, n ¼ 2;
gastrointestinal, n ¼ 2) treated with an initial dose of rhC1-INH
4200 IU in which the patient reported temporary improvement
in symptoms but required a second treatment (rhC1-INH 4200
IU [n ¼ 3] or icatibant 30 mg [n ¼ 1]) for symptom resolution.9
All 3 women in that earlier report delivered healthy, full-term
infants, with no congenital abnormalities reported.9
Safety data for HAE treatments during pregnancy are limited
because women who are pregnant are commonly excluded from
clinical trials during drug development for ethical reasons. Pa-
tients must rely on HAE treatment data from pharmacovigilance,
observational studies such as registries, case-control studies, and
surveillance methods to establish a knowledge base of treatment
and outcomes for pregnant women with HAE. As the knowledge
surrounding HAE treatments during pregnancy continues to
grow, this information will help women diagnosed with HAE
who are pregnant or planning to become pregnant make
informed treatment decisions in consult with their health care
providers. This review focused on the safety aspects of drug
exposure during pregnancy, and there were no apparent dose-
related safety findings. Although the series was not intended to
evaluate efficacy, there was no evidence for differential efficacy in
pregnant versus nonpregnant patients with HAE. In conclusion,
we report that treatment with rhC1-INH for HAE attacks in
pregnant women was generally safe and well tolerated. All 14
women in this study delivered healthy babies at full term without
complications.
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